Logo

American Heart Association

  200
  0


Final ID: P1034

Trends of Glucagon-Like Peptide 1 Receptor Agonist Usage, Self-Payments and Total Payments Among People Without Diabetes in the United States from 2017 -2022

Abstract Body: Introduction: While originally developed for glucose lowering, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight loss. With the recent FDA approval of GLP-1 RAs for weight management in 2021 and broadening indications for use, trends of GLP-1 RA use, self-payment, and total associated payments among people without diabetes has important clinical and policy implications.
Aim: We sought to describe trends of GLP-1 RA use, self-payments, and total associated payments among people without diabetes in the US from 2017 to 2022.
Methods: We analyzed data from the Medical Expenditure Panel Survey (MEPS) from 2017-2022 for individuals without diabetes who reported use of GLP-1 RA. MEPS is conducted by the Agency for Healthcare Research and Quality and uses survey instruments to collect demographic, health, and economic information on a nationally representative noninstitutionalized US population. Prescription use and payments were determined by self-report and confirmed with respondent pharmacy. The total payment and out-of-pocket payment for GLP-1 RA were averaged per person for each data year.
Results: A total of 148 participants representing 2,019,359 US adults without diabetes using GLP-1 RA were included. Mean (SD) age was 47.8 (14.7) years and 64.4% were female. The total weighted number of adults without diabetes who were prescribed GLP-1 RA increased 646% from 114,619 in 2017 to 854,728 in 2022 (p-value for trend < 0.01) with the greatest absolute increase between 2021-2022 (Figure). The average total payment increased from $2651 in 2017 to $6811 in 2022. The average self-payment decreased from $212 in 2017 to $157 in 2022. However, the changes were not statistically significant (p=0.3 for total payment; p=0.6 for self-payment).
Conclusion: GLP-1 RA use among people without diabetes has increased significantly between 2017-2022 with the greatest absolute increase following FDA approval for weight management in 2021.
  • Hammond, Michael  ( Northwestern University , Evanston , Illinois , United States )
  • Petito, Lucia  ( Northwestern University , Chicago , Illinois , United States )
  • Kazi, Dhruv  ( BIDMC , Boston , Massachusetts , United States )
  • Khan, Sadiya  ( Northwestern University , Oak Park , Illinois , United States )
  • Huang, Xiaoning  ( Northwestern University , Chicago , Illinois , United States )
  • Author Disclosures:
    Michael Hammond: DO NOT have relevant financial relationships | Lucia Petito: DO have relevant financial relationships ; Research Funding (PI or named investigator):Omron Healthcare Co., Ltd.:Active (exists now) ; Consultant:Ciconia Medical, LLC:Past (completed) | Dhruv Kazi: No Answer | Sadiya Khan: DO NOT have relevant financial relationships | Xiaoning Huang: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

PS01.03 Cardiometabolic Health and Disorders 1

Thursday, 03/06/2025 , 05:00PM - 07:00PM

Poster Session

More abstracts on this topic:
24-hour Movement Behaviors and BMI Among a National, Diverse Sample of Adolescents

Ajibewa Tiwaloluwa, Master Lindsay, Booker Robert, Wong Mandy, Reichenberger David, Mathew Gina, Buxton Orfeu, Chang Anne-marie, Hale Lauren


A blood test based on RNA-seq and machine learning for the detection of steatotic liver disease: A Pilot Study on Cardiometabolic Health

Poggio Rosana, Berdiñas Ignacio, La Greca Alejandro, Luzzani Carlos, Miriuka Santiago, Rodriguez-granillo Gaston, De Lillo Florencia, Rubilar Bibiana, Hijazi Razan, Solari Claudia, Rodríguez Varela María Soledad, Mobbs Alan, Manchini Estefania

More abstracts from these authors:
Area-level Social Determinants of Health Are Associated with Earlier Age of Heart Failure Onset: A Cluster Analysis in the Get With The Guidelines Heart Failure Registry

Huang Xiaoning, Ahmad Faraz, Shah Nilay, Yancy Clyde, Fonarow Gregg, Khan Sadiya, Petito Lucia

Framingham risk and major adverse cardiovascular events among patients with hypertension ineligible for SPRINT

Petito Lucia, Persell Stephen, Shah Nilay, Lloyd-jones Donald, Khan Sadiya, Huang Xiaoning, Jefferson Celeena, Vupputuri Suma, Lancki Nicola, Ahmad Faraz, Kazi Dhruv, Ndumele Chiadi, Allen Norrina

You have to be authorized to contact abstract author. Please, Login
Not Available